A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer

PIK3CA mutation frequency varies among breast cancer (BC) subtypes. Recent evidence suggests combination therapy with the PI3K inhibitor (PI3Ki) alpelisib and endocrine therapy (ET) improves response rates and progression-free survival (PFS) in PIK3CA-mutant, hormone receptor positive (HR+) BC versu...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Elizabeth J., Mollon, Lea E., Dean, Joni L., Warholak, Terri L., Aizer, Ayal, Platt, Emma A., Tang, Derek H., Davis, Lisa E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322582/
https://www.ncbi.nlm.nih.gov/pubmed/32637176
http://dx.doi.org/10.1155/2020/3759179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322582/
https://www.ncbi.nlm.nih.gov/pubmed/32637176
http://dx.doi.org/10.1155/2020/3759179

Ejemplares similares